Constructing a building is a complex, precarious process, which requires collaborative effort with particular focus on quality from all sides.
Pharma companies make substantial investments in their R&D laboratories, manufacturing facilities and quality management systems – not just because they are heavily regulated, but like any manufacturing industry, their customers expect and rely upon the product they purchase being of the requisite quality and performing, when used, in accordance with the clinical information published. Usually, pharma companies get their products right first time, whether these are generic drugs to be purchased over the counter or advanced therapy medical products.
Matthew Needham-Laing, head of construction at Stevens & Bolton LLP, has written an article recently featured in Pharmaceutical Manufacturing and Packing Sourcer, about how new technology advances in the construction industry are advantageous for both contractors and pharmaceutical companies.
To read a copy of the article in full, please click here.